Journal
FASEB JOURNAL
Volume 22, Issue 10, Pages 3509-3514Publisher
FEDERATION AMER SOC EXP BIOL
DOI: 10.1096/fj.08-110148
Keywords
NACP; PARK1; PD1; Western blot
Categories
Funding
- Swedish Research Council
- Swedish Brain Foundation
- Hallstens Forskningsstiftelse
- Swedish Parkinson Foundation
- Swedish Brain Power
- U.S. Public Health Service
- Ahlen's Foundation
- Karolinska Institutet Funds
Ask authors/readers for more resources
Alterations of brain and plasma a-synuclein levels and SNCA gene variability have been implicated in the pathogenesis of Parkinson's disease (PD). We therefore measured a-synuclein protein levels in postmortem PD and control cerebellum tissue using Western blot and investigated whether the levels correlated to SNCA genotype. We found markedly decreased a-synuclein levels in PD patients (n=16) compared to gender- and age-matched controls (n=14; P=0.004) normalized to a-tubulin. We also performed an association study of the noncoding polymorphisms rs2737029 (A/G) and rs356204 (A/G) (intron 4), and of rs356219 (T/C) (3'-region) of SNCA in a Swedish PD case-control material. Using a two-sided chi(2) test, we found significant association of rs2737029 (P=0.003; chi(2)=9.07) and rs356204 (P=0.048; chi(2)=3.91) with disease, strengthening the involvement of SNCA polymorphisms in sporadic PD. Stratification of the human postmortem brain material by genotype of the three investigated polymorphisms, did not indicate any influence of genotype on alpha-synuclein protein levels when comparing PD with controls. Taken together, our findings demonstrate that the investigated Parkinson patients have markedly reduced levels of a-synuclein in cerebellum, and that this reduction is general, rather then correlated to the investigated polymorphisms, although two of the polymorphisms also associated with disease in a Swedish material.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available